Metabolism and disposition of dasatinib after oral administration to humans

Drug Metabolism and Disposition : the Biological Fate of Chemicals
Lisa J ChristopherRamaswamy A Iyer

Abstract

SPRYCEL (dasatinib, BMS-354825; Bristol-Myers Squibb, Princeton, NJ), a multiple kinase inhibitor, is currently approved to treat chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia tumors in patients who are resistant or intolerant to imatinib mesylate (Gleevec; Novartis, Basel, Switzerland). After a 100-mg single p.o. dose of [(14)C]dasatinib to healthy volunteers, the radioactivity was rapidly absorbed (T(max) approximately 0.5 h). Both dasatinib and total radioactivity (TRA) plasma concentrations decreased rapidly with elimination half-life values of <4 h. Dasatinib was the major drug-related component in human plasma. At 2 h, dasatinib accounted for 25% of the TRA in plasma, suggesting that metabolites contributed significantly to the total drug-related component. There were many circulating metabolites detected that included hydroxylated metabolites (M20 and M24), an N-dealkylated metabolite (M4), an N-oxide (M5), an acid metabolite (M6), glucuronide conjugates (M8a,b), and products of further metabolism of these primary metabolites. Most of the administered radioactivity was eliminated in the feces (85%). Urine recovery accounted for <4% of the dose. Dasatinib accounted for <1 a...Continue Reading

References

Nov 1, 1991·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·T J JaworskiK K Midha
Dec 31, 1997·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·S C MitchellR L Smith
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Sep 24, 2004·Current Pharmaceutical Design·P H MaratheW G Humphreys
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Apr 19, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lisa J ChristopherRamaswamy A Iyer

❮ Previous
Next ❯

Citations

Sep 9, 2010·International Journal of Hematology·Yukako OnoShinichiro Okamoto
Mar 14, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xiaohai LiTomas Vojkovsky
Feb 25, 2009·Journal of Hematology & Oncology·Siu-Fun Wong
Feb 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric B HauraGerold Bepler
Jan 26, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard AplencPeter C Adamson
Apr 28, 2012·PloS One·Antonio Garcia-GomezMercedes Garayoa
Mar 5, 2013·PloS One·Deborah HuveldtPanos Z Anastasiadis
Mar 14, 2014·Bioanalysis·Anne-Françoise AubryMark E Arnold
Sep 21, 2012·Expert Opinion on Pharmacotherapy·Fabio P S Santos, Jorge Cortes
Aug 6, 2010·Expert Opinion on Drug Metabolism & Toxicology·Derek R Duckett, Michael D Cameron
Jan 31, 2015·Drug Development and Industrial Pharmacy·Yunfang ZhouJianshe Ma
Oct 14, 2014·Journal of Pharmaceutical Sciences·Jie ShaoGuohua An
Dec 21, 2010·Journal of Pharmaceutical and Biomedical Analysis·Anthony BarrosLisa J Christopher
Sep 8, 2009·Cancer Treatment Reviews·Nielka P van ErpHenk-Jan Guchelaar
May 17, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Yasuhiro TsumeGordon L Amidon
Dec 19, 2008·Clinical Pharmacology and Therapeutics·S D Baker, S Hu
Apr 28, 2011·Cancer·Heather D BrooksVassiliki A Papadimitrakopoulou
Jun 5, 2013·Head & Neck·Ying C HendersonGary L Clayman
Jan 15, 2013·Case Reports in Hematology·Nishant PatodiNaveen Sharma
Aug 5, 2015·Experimental Eye Research·Rintaro TsukaharaShigeo Tamiya
Feb 8, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Liyue HuangMin-Hwa Jasmine Lin
Feb 2, 2010·Renal Failure·Sultan OzkurtMehmet Soydan
Jan 18, 2013·Blood·Elisa ten HackenFederico Caligaris-Cappio
May 1, 2009·Bioanalysis·Olavi PelkonenHannu Raunio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.